EUROPEAN TRAINING CENTRES
Bialystok - Branicki Palace

 

Department of Nephrology and Transplantation, Bialystok Medical University, Bialystok, Poland

Peer Reviewed Publications in International Journals (only English) 2000-2003

Publicatons list


2001

1. Malyszko J., Wolczynski S., Zbroch E., Brzósko S., Malyszko J.S., Mysliwiec M. Correlation between Serum CrossLaps, urine DPD and serum ICTP in dialyzed patients. Nephron, 2001, 87, 283-285.
2. Barczyk M., Lebkowski W, Mariak Z., Malyszko J., Mysliwiec M. Brain abscess as a rare complication in hemodialysed patient. Case report. Med. Sci. Mon. 2001, 7, 1381-1385.
3. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int. 2001, 21, 158-165.
4. Pawlak D. Malyszko J. Buczko W. Mysliwiec M. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int J Urol Nephrol 2001, 33, 399-404.
5. Hryszko T, Malyszko J., Malyszko JS, Brzósko S, Pawlak K, Mysliwiec. A possible role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant, 2001, 16, 1692-1696.
6. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Simvastatin affects TAFI and thrombomodulin in CAPD patients. Thromb Haemost. 2001, 86, 900-901.
7. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Effects of long-term treatment with simvastatin on some hemostatic parameters in CAPD patients. Am J Nephrol 2001, 21, 373-378.
8. Brzósko S, Lebkowska U, Malyszko J, Hryszko T, Pawlak K, Mysliwiec M. Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. Clin Transplant 2001, 5, 349-353.
9. Hryszko T, Malyszko J., Malyszko JS, Brzósko S, Mysliwiec M. Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of Thrombin Activatable Fibrinolysis Inhibitor. Thromb Res 2001, 104, 322-328
10. Borawski J, Mysliwiec M. The hematocrit-corrected erythrocyte sedimentation rate can be useful in diagnosing inflammation in hemodialysis patients. Nephron 2001; 89: 381-383.
11. Borawski J, Mysliwiec M. Plasma fibrinogen level is an important determinant of prolonged euglobulin clot lysis time in hemodialysis patients. Clin Appl Thromb Hemost 2001; 7: 296-299.
12. Borawski J, Mysliwiec M. Soluble thrombomodulin: a marker of endothelial injury, an antithrombotic agent, or both? Med Sci Monit 2001; 7: 785-786.
13. Borawski J, Naumnik B, Pawlak K, Mysliwiec M. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001; 16: 1442-1447.
14. Borawski J, Naumnik B, Pawlak K, Mysliwiec M. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 787-792.
15. Brzósko S, Mysliwiec M, Donati MB, Iacoviello L. Homocysteinemia in patients with type 1 diabetes in relation to renal function. Diabetes Care 2001, 24, 2158
16. Braszko JJ, Kaminski KA, Hryszko T, Jedynak W, Brzosko S .Diverse effects of prolonged physical training on learning of the delayed non-matching to sample by rats.
Neurosci Res. 2001 Jan;39(1):79-84.

2002

17. Malyszko J, Wolczynski S, Malyszko JS, Mysliwiec M. Aluminium and beta-2-microglobulin in kidney transplant recipients. Transplant Proc. 2002, 34, 580-582.
18. Malyszko J, Lebkowska U, Wolczynski S, Malyszko JS, Mysliwiec M. Parathyroid glands on sonography in relation to some markers of bone metabolism in kidney transplant recipients. Transplant Proc. 2002, 34, 593-595.
19. Lebkowska U, Malyszko J, Brzósko S, Walecki J, Mysliwiec M. Thyroid gland function in patients after renal transplantation. Transplant Proc. 2002, 34, 596-597.
20. Malyszko J, Wolczynski S, Malyszko JS, Mysliwiec M. Correlation between new markers of bone formation-PICP and bone resorption-CrossLaps and ICTP in kidney transplant recipients. Transplant Proc. 2002, 34, 591-592.
21. Malyszko J, Malyszko JS, Brzósko S, Pawlak K, Mysliwiec M. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Ann Transplant 2002, 7, 32-34.
22. Malyszko J, Malyszko JS, Takada A, Mysliwiec M. Effects of immunosuppressive drug on platelet aggregation in vitro. Ann Transplant 2002, 7, 35-48.
23. Malyszko J., Wolczynski S., Zbroch E., Brzósko S., Malyszko J., Mysliwiec M. IGF system components in relation to erythropoietin therapy and bone metabolism in dialyzed patients and kidney transplant recipients. Nephron, 2002, 90, 282-289.
24. Malyszko J., Wolczynski S., Malyszko J., Mysliwiec M. Leptin correlates with some hemostatic parameters in CAPD patients. Nephron, 2002, 92, 721-724.
25. Malyszko J., Suchowierska E, Malyszko J.S., Mysliwiec M. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Perit Dial Int. 2002, 22, 582-592.
26. Malyszko J, Wolczynski S, Skrzydlewska E, Malyszko J. S., Mysliwiec M Vitamin K status in relation to bone metabolism in patients with renal failure. Am J Nephrol. 2002, 20, 505-508.
27. Azzadin A, Malyszko J, Malyszko JS., Tankiewicz A, Mysliwiec M, Buczko W. Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats. Pol J Pharmacol. 2002, 54, 469-473.
28. Malyszko J., Malyszko J.S., Mysliwiec M. Markers of endothelial cell injury and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in nephrotic syndrome. Blood Coagul Fibrinol 2002, 13, 625-631
29. Malyszko J., Suchowierska E, Malyszko J.S., Mysliwiec M. Some aspects of hemostasis in CAPD patients treated with erythropoietin. Kidney Blood Pres Res. 2002, 22, 240-244.
30. Malyszko J, Malyszko J S., Hryszko T, Wolczynski S, Mysliwiec M. Parvovirus B19 infection and IGF system components in relation to erythropoiesis in dialyzed patients and kidney transplant recipients. Transplant. Proc. 2002, 34, 3211-3214.
31. Malyszko J, Malyszko J S., Hryszko T, Brzosko S, Mysliwiec M. Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis. Int J Tissue Reactions 2002, 24, 111-115
32. Borawski J, Naumnik B, Mysliwiec M. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease and erythropoietin therapy. Clin Appl Thromb Hemost 2002; 8: 359-367.
33. Borawski J, Pawlak K, Naumnik B, Mysliwiec M. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients. Ren Fail 2002; 24: 825-837.
34. Naumnik B, Borawski J, Pawlak K, Mysliwiec M. Effect of hemodialysis on plasma levels of vascular endothelial markers. Clin Appl Thromb Hemost 2002; 8: 245-250.
35. Borawski J, Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost 2002; 8: 77-84.
36. Borawski J, Naumnik B, Mysliwiec M. Increased soluble thrombomodulin does not always indicate endothelial injury. Clin Appl Thromb Hemost 2002; 8: 87-89.
37. Borawski J, Mysliwiec M. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 637-644.
38. Naumnik B, Borawski J, Pawlak K, Mysliwiec M. Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers. Nephrol Dial Transplant 2002; 17: 526-528.
39. Borawski J, Pawlak K, Mysliwiec M. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients. Nephron 2002; 91: 671-681.
40. Borawski J, Mysliwiec M. Hemoglobin level is an important determinant of acid-base status in hemodialysis patients. Nephron 2002; 90: 111-113.
41. Brzosko S., Hryszko T., Zak J., Wysocka J, Mysliwiec M.: Platelet glycoprotein Ib and reactivity of platelets in diabetic and non-diabetic hemodialysed patients. Thromb. Haemostas. 2002, 87, 344-345.
42. Brzosko S, De Curtis A, Murzilli S, de Gaetano G, Donati MB, Iacoviello L.Effect of extra virgin olive oil on experimental thrombosis and primary hemostasis in rats. Nutr Metab Cardiovasc Dis. 2002 Dec;12:337-42.
43.

Brzosko S, Krauze-Brzosko K, de Gaetano G, Iacoviello L.Asymmetrical dimethylarginine and risk of acute coronary events. Lancet. 2002 ;359:1620.



2003

44. Malyszko J., Malyszko J.S., Mysliwiec M. Fluvastatin affects TAFI concentration in kidney transplant recipients. Transplant Int. 2003, 16, 53-57.
45. Malyszko J., Skrzydlewska E, Malyszko J.S., Mysliwiec M. Protein Z, vitamin K-dependent protein, in patients with renal failure. J Thromb Haemostas 2003, 1, 195-196.
46. Zbroch E., Malyszko J., Kamocki Z., Mysliwiec M. Pneumomediastinum and pneumatosis subcutaneous–unusual complications of automated peritoneal dialysis. Perit Dial Int 2003, 23, 97-98.
47. Lebkowska U, Malyszko JS, Malyszko J, Walecki J, Dzieciol J, Mysliwiec M. Thyroid function and “incidentalomas” in kidney transplant recipients. Med. Sci. Mon. 2003, 9, MT8-11
48. Malyszko J., Malyszko J.S., Hryszko T, Mysliwiec M. Influence of simvastatin on aspects of thrombogenesis in peritoneally dialyzed-CAPD patients. Perit. Dial. Int. 2003, 23, 26-266.
49. Malyszko J, Wolczynski S, Konstantynowicz J, Malyszko JS, Kaczmarski M, Mysliwiec M. New markers of bone formation and bone resorption and their correlations with DEXA in kidney transplant recipients. Transplant Proc. 2003, 35, 1351-1354.
50. Malyszko J, Wolczynski S, Malyszko JS, Mysliwiec M. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. Transplant Proc. 35, 2227-2229.
51. Malyszko J, Malyszko JS, Hryszko T., Mysliwiec M. Thrombin Activatable Fibrinolysis Inhibitor-TAFI in kidney transplant recipient with dyslipidemia Transplant Proc. 2003, 35, 2219-2221.
52. Lebkowska U, Malyszko J, Lebkowski WJ, Walecki J, Mysliwiec M. Is there a correlation between thyroid function and renal function in kidney transplant recipients? Transplant Proc. 2003, 35, 2222-2223.
53. Lebkowska U, Malyszko J, Mysliwiec M. Thyroid function and morphology in kidney transplant recipients, hemodialyzed and peritoneally dialyzed patients. Transplant Proc. 2003, 35, 2945-8
54. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine and prednisone in comparison to patients treated with cyclosporine and prednisone" Transplant Proc. 2003, 35, 2940-2942
55. Brzosko S, Hryszko T, Lebkowska U, Malyszko J, Malyszko JS, Mysliwiec M. Plasma tissue-type plasminogen activator, fibrinogen, and time on dialysis prior to transplantation are related to carotid intima media thickness in renal transplant recipients. Transplant Proc. 2003, 35, 2931-2934
56. Borawski J, Naumnik B, Mysliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin. Kidney Int 2003; 64: 2229-2237.
57. Borawski J, Naumnik B, Mysliwiec M. Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis. Nephrol Dial Transplant 2003; 18: 1680-1682.
58. Borawski J, Naumnik B, Mysliwiec M. Serum a1-antitrypsin but not complement C3 and C4 predicts chronic inflammation in hemodialysis patients. Ren Fail 2003; 25: 589-593.
59. Pawlak K, Borawski J, Naumnik B, Mysliwiec Relationship between oxidative stress and extrinsic coagulation pathway in haemodialysis patients. Thromb Res 2003; 109: 247-251.
60. Borawski J, Naumnik B, Mysliwiec M. Hepatocyte growth factor: a possible mediator of heparin-induced osteoporosis? Clin Appl Thromb Hemost 2003; 9: 171-172.
61. Borawski J, Naumnik B, Mysliwiec M. Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients. Clin Appl Thromb Hemost 2003; 9: 173-174.
62. Naumnik B, Borawski J, Mysliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis. Nephrol Dial Transplant 2003; 18: 1376-1382.
63. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003 ;63 :2771-4.
64. Borawski J, Naumnik B, Mysliwiec M. Circulating endothelial markers and probability of stroke in haemodialysis patients. Blood Coagul Fibrinolysis 2003; 14: 315-317.

 

2004

65. Hryszko T, Brzosko S, Mazerska M, Malyszko J, Mysliwiec M. Risk factors of nontunneled noncuffed hemodialysis catheters mulfunction. Nephron 2004
66. Malyszko J, Malyszko JS, Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis (CAPD). Kidney Blood Press Res. 2004
67. Lebkowska U,Malyszko J, Walecki J, Mysliwiec M. Thyroid volume, structure and thyroid function in hemodialyzed and peritoneally dialyzed patients. Pol J Radiol 2004.
68. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb Haemostas 2004